Auteurs
Analysis
France
Racine
Analysis
France
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Olivier Blin »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Olivier Blanc < Olivier Blin < Olivier Cottencin  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
000206 (2010) Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
000261 (2009) Gabriel Robert [France] ; Dominique Drapier [France] ; Marc Verin [France] ; Bruno Millet [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology
000406 (2005) Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
000616 (1995) Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France]Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
000629 (1994) Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France]Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

List of associated KwdEn.i

Nombre de
documents		Descripteur
5Humans
4Parkinson Disease (drug therapy)
4Parkinson disease
4Parkinson's disease
3Aged
3Dose-Response Relationship, Drug
3Female
3Human
3Male
3Nervous system diseases
2Cross-Over Studies
2Double blind study
2Double-Blind Method
2Drug Therapy, Combination
2Levodopa (adverse effects)
2Middle Aged
2Neurologic Examination (drug effects)
2Piribedil
2Severity of Illness Index
2Single dose
2Treatment Outcome
2piribedil
1Administration, Sublingual
1Akinesia
1Antidepressant agent
1Antiparkinson Agents (administration & dosage)
1Apomorphine (administration & dosage)
1Bromocriptine (adverse effects)
1Bromocriptine (therapeutic use)
1Cognition (physiology)
1Decision Making (physiology)
1Deep Brain Stimulation (adverse effects)
1Disability Evaluation
1Dopamine
1Dopamine (metabolism)
1Dopamine Agents (adverse effects)
1Dopamine Agonists (blood)
1Dopamine Agonists (therapeutic use)
1Dopamine agonist
1Drug Administration Routes
1Drug Evaluation (methods)
1Dyskinesia, Drug-Induced (drug therapy)
1Fluctuations
1Fluoxetine (administration & dosage)
1Fluoxetine (adverse effects)
1France
1Impulsive Behavior (etiology)
1Infusions, Intravenous (methods)
1Intravenous administration
1Levodopa (administration & dosage)
1Levodopa (therapeutic use)
1Logistic Models
1Motor Skills (drug effects)
1Motor symptoms
1Naltrexone
1Naltrexone (adverse effects)
1Naltrexone (therapeutic use)
1Neuropsychological Tests
1Parkinson Disease (blood)
1Parkinson Disease (complications)
1Parkinson Disease (therapy)
1Parkinson Disease, Secondary (chemically induced)
1Parkinson Disease, Secondary (diagnosis)
1Parkinsonian syndrome
1Pathophysiology
1Pharmacodynamics
1Pharmacokinetics
1Pilot Projects
1Piribedil (administration & dosage)
1Piribedil (blood)
1Piribedil (therapeutic use)
1Placebo
1Previous study
1Proportional Hazards Models
1Prospective Studies
1Retrospective Studies
1Reward
1S90049
1Subthalamic nucleus
1Time Factors
1Toxicity
1akinesia
1apomorphine
1dopamine
1dopamine agonist
1impulsivity
1intravenous
1limbic
1motor fluctuations
1pharmacokinetics/pharmacodynamics
1randomized double‐blind study
1subthalamic nucleus

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Olivier Blin" 

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Olivier Blin" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Olivier Blin
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024